Case Report · Description de cas · Fallbericht
Effective Treatment with Topical Cyclosporin A of a Patient with Cogan SyndromeShimura M. · Yasuda K. · Fuse N. · Nakazawa M. · Tamai M.
Department of Ophthalmology, School of Medicine, Tohoku University, Sendai, Miyagi, Japan
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
The purpose of this report is to describe the effective treatment of severe anterior segment inflammation due to Cogan syndrome through the use of topical administration of cyclosporin A. A 47-year-old female patient had been experiencing headaches and difficulties with her vision. Subsequent examination revealed the sudden onset of bilateral conjunctival injection and swelling of bilateral auricles. Despite the multiple treatment (systemic and topical corticosteroid and antibiotic therapy), necrotizing scleritis had appeared bilaterally and the scleral wall was thinning. Topical administration of 1% cyclosporin A was applied to both eyes 4 times a day. After 2 months of this therapy, the epithelial tissue covered the necrotizing tissue and her symptom of ocular pain was relieved and her corrected visual acuity was improved. This is the first case exhibiting that topical cyclosporin A is an effective treatment for severe anterior segment inflammation associated with Cogan syndrome.
© 2000 S. Karger AG, Basel
Norton EWD, Cogan DG: Syndrome of nonsyphilitic interstitial keratitis and vestibuloauditory symptoms. A long-term follow-up. Arch Ophthalmol 1959;61:695–697.
Cogan DG: Syndrome of nonsyphilitic interstitial keratitis and vestibuloauditory symptoms. Arch Ophthalmol 1945;33:144–149.
- Haynes BF, Kaiser-Kupfer MI, Mason P, Fauci AS: Cogan syndrome: Studies in thirteen patients, long-term follow-up, and a review of the literature. Medicine (Baltimore) 1980;59:426–441.
Svitra PP, Perry H: Vogt-Koyanagi-Harada (uveomeningic) syndrome; in Albert DM, Jakobiec FA (eds): Principles and Practice of Ophthalmology. Philadelphia, Saunders, 1994, vol 1, pp 481–488.
- Ellner JJ, Bennett JE: Chronic meningitis. Medicine (Baltimore) 1976;55:341–369.
- LaRaja RD: Cogan syndrome associated with mesenteric vascular insufficiency. Arch Surg 1976;111:1028–1031.
- Bicknell JM, Holland JV: Neurologic manifestations of Cogan syndrome. Neurology 1978;28:278–281.
- Oldenski R: Cogan syndrome: Autoimmune-mediated audiovestibular symptoms and ocular inflammation. J Am Board Fam Pract 1993;6:577–581.
- Sergent JS, Lockshin MD, Christian CL, Gocke DJ: Vasculitis with hepatitis B antigenemia. Medicine (Baltimore) 1976;55:1–18.
- Duffy J, Lidsky MD, Sharp JT, Davis JS, Person DA, Hollinger FB, Min KW: Polyarthritis, polyarteritis, and hepatitis B. Medicine (Baltimore) 1976;55:19–37.
- Murray PI, Rahi AH: Pathogenesis of Mooren’s ulcer: Some new concepts. Br J Ophthalmol 1984;68:182–187.
- Holland EJ, Olsen TW, Ketcham JM: Topical cyclosporin A in the treatment of anterior segment inflammatory disease. Cornea 1993;12:413–419.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.